The latest report by IMARC Group, titled “mRNA Vaccines and Therapeutics Market Report by Vaccine Type (Self-amplifying mRNA-Based Vaccines, Conventional Non-Amplifying mRNA-Based Vaccines), Treatment Type (Bioengineered Vaccine, Gene Therapy, Gene Transcription, Cell Therapy, Monoclonal Antibody, and Others), Vaccine Manufacturing (In-House, Out-Sourced), Application (Cancer, Infectious Disease, Gene Editing, Protein Replacement), End-User (Hospitals and Clinics, Research Organizations, and Others), and Region 2024-2032“, The global mRNA vaccines and therapeutics market size reached US$ 57.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 72.7 Billion by 2032, exhibiting a growth rate (CAGR) of 2.53% during 2024-2032.
Factors Affecting the Growth of the mRNA Vaccines Therapeutics Industry:
- Increasing Investment and Funding in mRNA Vaccine Research:
The global market for vaccine research is witnessing a significant influx of investment and funding directed toward mRNA technology, particularly in the wake of the COVID-19 pandemic. Pharmaceutical companies, governments, and private investors recognize the potential of mRNA vaccines to respond rapidly to infectious diseases and are thus committing substantial resources to advance this field. Moreover, this financial backing supports extensive research and development (R&D) activities, from preclinical studies to clinical trials, facilitating quicker progress from laboratory to market. These investments are propelling innovations in vaccine technology and expanding the infrastructure required for large-scale production and distribution.
- Advancements in Drug Delivery:
The recent advancements in drug delivery systems, notably lipid nanoparticle (LNP) technology, have marked a significant milestone in the development of mRNA vaccines. LNPs are microscopic particles that effectively encapsulate mRNA molecules to protect them from degradation before they can reach their target cells. Improvements in LNP formulations have led to increased stability, efficacy, and safety of mRNA vaccines. Moreover, enhanced stability ensures that vaccines retain their integrity under various transportation conditions, extending their reach to broader populations. Besides this, the improved efficacy is seen in the potent immune responses generated by these vaccines, which are crucial for the prevention of severe diseases.
- Growing Acceptance and Public Awareness:
The successful deployment of mRNA vaccines during the COVID-19 pandemic has significantly increased public acceptance and awareness of this technology. Additionally, mRNA vaccines have demonstrated their safety and effectiveness, leading to a shift in public perception. The widespread media coverage and public health campaigns educated the population on the benefits and mechanisms of mRNA vaccines, fostering a better understanding and trust in the science behind them. Besides this, the shift is crucial for the future of mRNA therapeutics as it paves the way for broader acceptance of vaccines for other diseases. Moreover, the readiness of the public to accept mRNA-based treatments is likely to accelerate the adoption of new vaccines and therapies, thereby expanding their use in preventive medicine and beyond.
Competitive Landscape with Key Player:
- Arcturus Therapeutics Inc.
- BioNTech SE
- CureVac AG
- eTheRNA immunotherapies NV
- ethris GmbH
- GlaxoSmithKline PLC
- Moderna Therapeutics Inc.
- Translate Bio Inc.
- Argos Therapeutics, Inc.
- Sangamo Therapeutics Inc.
- Pfizer Inc.
For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/mrna-vaccines-therapeutics-market/requestsample
Report Segmentation:
The report has segmented the market into the following categories:
Breakup by Vaccine Type:
- Self-amplifying mRNA-Based Vaccines
- Conventional Non-Amplifying mRNA-Based Vaccines
Conventional non-amplifying mRNA-based vaccines represent the largest segment due to Top of Formtheir established safety profiles and ease of production.
Breakup by Treatment Type:
- Bioengineered Vaccine
- Gene Therapy
- Gene Transcription
- Cell Therapy
- Monoclonal Antibody
- Others
Bioengineered vaccines account for the largest market share, owing to their ability to target specific diseases with enhanced efficacy and reduced side effects.
Breakup by Vaccine Manufacturing:
- In-House
- Out-Sourced
In-house manufacturing holds the largest market share owing to companies’ desire for greater control over production processes and quality assurance.
Breakup by Application:
- Cancer
- Infectious Disease
- Gene Editing
- Protein Replacement
Infectious diseases account for the largest market share, Top of Formowdue sdue to the pressing need for effective solutions against prevalent diseases.
Breakup by End-User:
- Hospitals and Clinics
- Research Organizations
- Others
Hospitals and clinics dominate the market owing to their pivotal role in vaccine distribution and patient care infrastructure.
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Europe’s dominance in the mRNA vaccine therapeutics market is attributed to the growing healthcare systems, supportive regulatory frameworks, and high demand for innovative vaccine solutions.
Global mRNA Vaccines Therapeutics Market Trends:
At present, the mRNA vaccine technology is gaining immense attention due to its rapid development and successful deployment during the COVID-19 pandemic. The unprecedented speed at which mRNA vaccines such as Pfizer-BioNTech and Moderna were developed and approved has demonstrated the potential of this technology in responding to emerging infectious diseases. Moreover, the ongoing advancements in mRNA technology, including improvements in delivery systems, stability, and scalability, are driving innovation in vaccine development and therapeutics. Novel delivery methods, such as lipid nanoparticles, are enhancing the efficiency and efficacy of mRNA vaccines, while efforts to optimize manufacturing processes are aimed at scaling up production to meet global demand.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
